SCLX vs GSK
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Sep 21, 2026
SCLX
GSK
Investment Advisor Scores
GSK
AI Analyst Insights
Detailed Metrics Comparison
| Metric | SCLX | GSK | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 5.5772 | 9.5969 | SCLX |
| PEG Ratio | 0 | 6.0006 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | -22.8% | 5.3% | GSK |
| Earnings Growth | 0.0% | -69.5% | SCLX |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 51.1/100 | 54.2/100 | GSK |
| Profit Margin | 0.0% | 14.5% | GSK |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | STRONG BUY | GSK |
Relative Price Performance (Last 90 Days)
Current Technical Phase
SCLX
MarkdownPrice below a falling SMA50 (slope -16.9%), weak momentum, RSI 31
GSK
DistributionPrice near a flattening SMA50 (slope -1.8%) with fading momentum, RSI 47
Fundamentals Snapshot
| Metric | SCLX | GSK |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 6.2 | 9.9 |
| Trailing P/E | — | 15.8 |
| Revenue (TTM) | — | — |
| Revenue Growth | -0.2% | 0.1% |
| Gross Margin | 0.6% | 0.7% |
| Operating Margin | -3.9% | 0.3% |
| EPS | -49.73 | 3.11 |
| Dividend Yield | — | 0.04% |